| Literature DB >> 24357813 |
Caroline A Flurey1, Marianne Morris, Pam Richards, Rodney Hughes, Sarah Hewlett.
Abstract
OBJECTIVE: The objective of this study was to explore patients' experiences of RA daily life while on modern treatments.Entities:
Keywords: daily life; flare; help-seeking; impact; interviews; qualitative; rheumatoid arthritis
Mesh:
Year: 2013 PMID: 24357813 PMCID: PMC3970565 DOI: 10.1093/rheumatology/ket416
Source DB: PubMed Journal: Rheumatology (Oxford) ISSN: 1462-0324 Impact factor: 7.580
Interview topic guide
Can you tell me what your daily life with RA is like? Can you tell me about how your daily symptoms vary? How do you manage your daily symptoms? What words would you use to describe the daily variation in your symptoms? What happens when you have a period of high disease activity? How can you tell that this period of high disease activity or flare is different from daily symptom variation? Do you get early warning signs that a flare is coming? How do you manage a flare? How do you decide when it is time to see a member of the rheumatology team? If we could measure a flare on a scale, what would the points on the scale say? Do you have anything else you would like to mention that we’ve not discussed? |
Individual interviewees’ demographic and disease-related data (n = 15)
| Patient number | Gender | Age, years | Disease duration, years | HAQ | PtG | Current medication |
|---|---|---|---|---|---|---|
| Participant 1 | Female | 44 | 23 | 2.75 | 3.8 | Anti-TNF, DMARDs, NSAIDs |
| Participant 2 | Female | 45 | 25 | 2.38 | 4.0 | NSAIDs |
| Participant 3 | Female | 37 | 19 | 0.63 | 2.4 | DMARDs, NSAIDs |
| Participant 4 | Female | 42 | 20 | 1.00 | 3.3 | DMARDs |
| Participant 5 | Male | 48 | 10 | 0.25 | 3.0 | Anti-TNF, DMARDs, steroids |
| Participant 6 | Male | 56 | 13 | 0.25 | 3.5 | Anti-TNF, DMARDs |
| Participant 7 | Female | 67 | 9 | 2.38 | 7.8 | DMARDs |
| Participant 8 | Female | 65 | 16 | 2.75 | 2.8 | Anti-TNF, NSAIDs |
| Participant 9 | Female | 35 | 4 | 1.50 | 1.7 | DMARDs |
| Participant 10 | Female | 51 | 5 | 0.13 | 1.1 | DMARDs |
| Participant 11 | Female | 77 | 30 | n/d | 4.6 | Anti-TNF, DMARDs |
| Participant 12 | Male | 47 | 5 | 0.00 | 0.9 | DMARDs |
| Participant 13 | Female | 59 | 3 | 0.88 | 3.1 | DMARDs |
| Participant 14 | Female | 52 | 23 | 1.88 | 1.9 | DMARDs, NSAIDs |
| Participant 15 | Female | 42 | 17 | 1.75 | 4.8 | DMARDs, steroids |
| Mean | 51.1 | 14.8 | 1.30 | 3.3 | — | |
| 11.8 | 8.6 | 1.00 | 1.7 | — | ||
| Range | 35–77 | 3–30 | 0–2.75 | 0.9–7.8 | — |
HAQ: 0–3, 3 = severe disability; PtG: patient global element of the DAS, 0–10, 10 = severe disease.
FMediation ladder
FPreliminary fluctuating balances model